5,6,7,8-四氢-咔唑-3-羧酸酰胺 | 105973-96-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5,6,7,8-四氢-咔唑-3-羧酸酰胺
• 英文名称: 5,6,7,8-tetrahydro-carbazole-3-carboxylic acid amide
• 英文别名: 5,6,7,8-Tetrahydro-carbazol-3-carbonsaeure-amid；2,3,4,9-Tetrahydro-1h-carbazole-6-carboxamide；6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
• CAS: 105973-96-4
• 化学式: C₁₃H₁₄N₂O
• mdl: MFCD00468992
• 分子量: 214.267
• InChiKey: JBNWVOPWJLKUPN-UHFFFAOYSA-N

物化性质

• 熔点：
  217-219 °C
• 沸点：
  488.2±40.0 °C(Predicted)
• 密度：
  1.279±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.307
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5,6,7,8-四氢-咔唑-3-羧酸酰胺 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 (6,7,8,9-四氢-5H-咔唑-3-基)甲胺
  参考文献：
  名称：

  Indole Carboxamidines and Aminomethylindoles as Antimetabolites of Serotonin

  摘要：

  DOI：

  10.1021/ja01570a069
• 作为产物：
  描述：

  环己酮 、 alkaline earth salt of/the/ methylsulfuric acid 生成 5,6,7,8-四氢-咔唑-3-羧酸酰胺
  参考文献：
  名称：

  Indole Carboxamidines and Aminomethylindoles as Antimetabolites of Serotonin

  摘要：

  DOI：

  10.1021/ja01570a069

文献信息

• [EN] TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM<br/>[FR] DERIVES DE PYRAZOLE TETRACYCLIQUE UTILISES COMME INHIBITEURS DE KINASE, PROCESSUS DE PREPARATION CORRESPONDANT ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT
  申请人：PHARMACIA ITALIA SPA

  公开号：WO2004071507A1

  公开（公告）日：2004-08-26

  The present invention provides a method for treating diseases caused by and/or associated with an altered protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a tetracyclic pyrazole. The invention also provides specific tetracyclic pyrazole derivatives, useful intermediates, a library comprising at least two of them, a process for their preparation and the pharmaceutical compositions containing them, which are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, viral infections, autoimmune diseases and neurodegenerative disorders.

  本发明提供了一种治疗由改变的蛋白激酶活性引起和/或与之相关的疾病的方法，包括向需要的哺乳动物施用有效量的四环吡唑。该发明还提供了特定的四环吡唑衍生物、有用的中间体、包含至少两种中间体的库、它们的制备方法以及含有它们的药物组合物，这些药物组合物在治疗由改变的蛋白激酶活性引起和/或与之相关的疾病方面具有用处，如癌症、细胞增殖障碍、病毒感染、自身免疫疾病和神经退行性疾病。
• Fused indolecarboxamides: dopamine receptor subtype specific ligands
  申请人：Neurogen Corporation

  公开号：US06175015B1

  公开（公告）日：2001-01-16

  Disclosed are compounds of the formula: or the pharmaceutically acceptable acid addition salts thereof wherein: R1 and R2 are the same or different and represent hydrogen, C1-C6 alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C1-C6 alkoxy, —O2CR′, —NHCOR′, —COR′, —SOmR′, where R′ is C1-C6 alkyl and wherein m is 0, 1 or 2; or R1 and R2 independently represent —CONR′R″, or —NR′R″ where R′ and R″ independently represent hydrogen or C1-C6 alkyl; R3 is hydrogen, C1-C6 alkyl, or —COR′″ where R′″ is C1-C6 alkyl; R4 is hydrogen or C1-C6 alkyl; and R represents an azacycloalkylalkyl group, which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dysronia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention are useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.

  公开了以下化合物的结构式：或其药物可接受的酸盐，其中：R1和R2相同或不同，代表氢，C1-C6烷基，卤素，羟基，氨基，氰基，硝基，三氟甲基，三氟甲氧基，C1-C6烷氧基，—O2CR′，—NHCOR′，—COR′，—SOmR′，其中R′为C1-C6烷基，m为0、1或2；或R1和R2独立地代表—CONR′R″，或—NR′R″，其中R′和R″独立地代表氢或C1-C6烷基；R3代表氢，C1-C6烷基，或—COR′″，其中R′″为C1-C6烷基；R4代表氢或C1-C6烷基；R代表一个含氮杂环烷基烷基，这些化合物在治疗情感障碍，如精神分裂症、抑郁症、阿尔茨海默病、运动障碍，如帕金森病和失调症，以及其他对多巴胺能阻滞有反应的疾病，如物质滥用和强迫性障碍方面有用。此外，本发明的化合物在治疗与传统神经类药物使用相关的外展侧面影响方面有用。
• [EN] CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS<br/>[FR] PROCÉDÉS ET PRÉCURSEURS DE TRYPTAMINE CATALYTIQUES
  申请人：KARE CHEMICAL TECH INC

  公开号：WO2022232931A1

  公开（公告）日：2022-11-10

  The present disclosure relates to the use of tryptamine precursor compounds and zinc amide enolate compounds for the preparation of tryptamines. The disclosure also relates to the use of catalysts and catalytic processes for the preparation of tryptamines using the zinc amide enolate compounds and the tryptamine precursor compounds.

  本公开涉及使用色胺前体化合物和锌酰胺烯醇化合物制备色胺。该公开还涉及使用催化剂和催化过程，使用锌酰胺烯醇化合物和色胺前体化合物制备色胺。
• 5-HYDROXYTRYPTAMINE 1B RECEPTOR-STIMULATING AGENT FOR USE AS A PROMOTER OF SATELLITE CELLS SELF-RENEWAL AND/OR DIFFERENTIATION
  申请人：Institut Pasteur

  公开号：EP3799873A1

  公开（公告）日：2021-04-07

  The present invention relates to the field of muscle regeneration, and more particularly to the replenishment of the in vivo muscle stem cells pool. It more specifically relates to a 5-hydroxytryptamine B1 receptor-stimulating agent, and to a composition comprising said agent, for use as i) a promoter of satellite cells self-renewal and/or differentiation, and/or ii) an agent preventing and/or inhibiting the satellite cells pool exhaustion. The invention further encompasses therapeutic and screening methods.

  本发明涉及肌肉再生领域，特别是体内肌肉干细胞池的补充。本发明更具体地涉及一种5-羟色胺B1受体刺激剂，以及一种包含上述刺激剂的组合物，可用作i）卫星细胞自我更新和/或分化的促进剂，和/或ii）防止和/或抑制卫星细胞池耗竭的药物。本发明还包括治疗和筛选方法。
• FUSED INDOLECARBOXAMIDES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS
  申请人：NEUROGEN CORPORATION

  公开号：EP0923574A1

  公开（公告）日：1999-06-23